bioRxiv Science⌕ Search

Biology subjects

Wise, J. F.

Publications and source records attributed to Wise, J. F..

2 recordsLinked to original sources

Deep Learning Based Identification of Tissue of Origin for Carcinomas of Unknown Primary utilizing micro-RNA expression

Carcinoma of Unknown Primary (CUP) is a subset of metastatic cancers in which the primary tissue source, or origin, remains unidentified. CUP accounts for three to five percent of all malignancies [2]. Representing an exceptionally aggressive category of metastatic cancers, the median survival of those diagnosed with CUP is approximately three to six months [1]. The tissue in which a cancer arises plays a key role in our understanding of altered gene expression, altered cellular pathways, and sensitivities to various forms of cell death in cancer cells [3]. Thus, the lack of knowledge on tissue of origin makes it difficult to devise tailored treatments for patients with CUP [4]. Developing clinically implementable methods to identify the tissue of origin of the primary site is crucial in treating CUP patients [4]. In particular, the expression profiles of non-coding RNAs can provide insight into the tissue of origin for CUP. Non-coding RNAs provide a robust route to clinical implementation due to their resistance against chemical degradation [5]. In this work, we investigate the potential of microRNAs as highly accurate biomarkers for detecting the tissue of origin for metastatic cancers. We further hypothesize that data driven approaches can identify specific microRNA biomarker targets. We used microRNA expression data from the Cancer Genome Atlas (TCGA) dataset [6] and assessed various machine learning approaches. Our results show that it is possible to design robust classifiers to detect the tissue of origin for metastatic samples on the TCGA dataset with an accuracy of up to 96%, which may be utilized in situations of CUP. As a validation of our classifiers, we evaluated the accuracy on a separate set of 194 primary tumor samples from the Sequence Read Archive (SRA) [7]. Our findings demonstrate that deep learning techniques enhance prediction accuracy. We progressed from an initial accuracy prediction of 62.5% with decision trees to 93.2% with logistic regression, finally achieving 96.1% accuracy using deep learning on metastatic samples. On the SRA validation set, a lower accuracy of 41.2% was achieved by decision tree, while deep learning achieved a higher accuracy of 81.2%. Notably, our feature importance analysis showed the top three important biomarkers for predicting tissue of origin to be mir-10b, mir-205, and mir-196b, which aligns with previous work [10]. Our findings highlight the potential of using machine learning techniques to devise tests for detecting tissue of origin for CUP. Since microRNAs are carried throughout the body via vesicles secreted from cells, they may serve as key biomarkers for liquid biopsy due to their presence in blood plasma [11]. Our work serves as a foundation towards developing blood-based cancer detection tests based on microRNA presence.

cancer biology↗

Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC paralogs

Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients but has been difficult to capture in laboratory models. Here we present a pre-clinical system that recapitulates acquired cross-resistance in SCLC, developed from 51 patient-derived xenografts (PDXs). Each model was tested for in vivo sensitivity to three clinical regimens: cisplatin plus etoposide, olaparib plus temozolomide, and topotecan. These functional profiles captured hallmark clinical features, such as the emergence of treatment-refractory disease after early relapse. Serially derived PDX models from the same patient revealed that cross-resistance was acquired through a MYC amplification on extrachromosomal DNA (ecDNA). Genomic and transcriptional profiles of the full PDX panel revealed that this was not unique to one patient, as MYC paralog amplifications on ecDNAs were recurrent among cross-resistant models derived from patients after relapse. We conclude that ecDNAs with MYC paralogs are recurrent drivers of cross-resistance in SCLC. SIGNIFICANCESCLC is initially chemosensitive, but acquired cross-resistance renders this disease refractory to further treatment and ultimately fatal. The genomic drivers of this transformation are unknown. We use a population of PDX models to discover that amplifications of MYC paralogs on ecDNA are recurrent drivers of acquired cross-resistance in SCLC.

cancer biology↗